BuqiTongluo Granule for Ischemic Stroke, Stable Angina Pectoris, Diabetic Peripheral Neuropathy with Qi Deficiency and Blood Stasis Syndrome: Rationale and Novel Basket Design

Weidi Liu, Li Zhou, Luda Feng, Dandan Zhang, Chi Zhang, Ying Gao, behalf of the BOSS Group, Weidi Liu, Li Zhou, Luda Feng, Dandan Zhang, Chi Zhang, Ying Gao, behalf of the BOSS Group

Abstract

Background: BuqiTongluo (BQTL) granules are herbal phenotypic drugs for Qi deficiency and blood stasis (QDBS) syndrome. Its discovery relied primarily on knowledge of observable phenotypic changes associated with diseases. Although BQTL granules have been widely advocated by Chinese Medicine (CM) practitioners, its use lacks empirical support. Aim of the study: In this basket trial, the efficacy of BQTL granules in multiple diseases that have the QDBS syndrome in common will be compared with placebo. Materials and Methods: The BuqiTongluo granule for Qi deficiency and blood stasis syndrome (BOSS) study is a basket herbal trial (ClinicalTrials.gov, NCT04408261). It will be a double-blinded, randomized, placebo-controlled, parallel, multicenter, clinical trial. In total, 432 patients (1:1:1 ischemic stroke, stable angina pectoris, and diabetic peripheral neuropathy), who meet the operationalized diagnostic criteria for QDBS syndrome, have been recruited and randomized in a ratio of 1:1 to receive 6 weeks' treatment with BQTL granules or placebo. The primary outcome is the change in the QDBS syndrome score at week 6 from baseline. Secondary outcomes include objective outcome measures for the three diseases and adverse events. Omics will help to understand these responses by molecular events. Conclusion: QDBS syndrome is a common phenotypic marker that was hypothesized to predict whether patients with multiple diseases would respond to this targeted therapy. No previous basket trial has assessed the potential efficacy of an herbal intervention for multiple diseases. The unique promise of the trial is its ability to exploit a disease phenotype to discover novel treatments for three diseases for which the root cause is unknown, complex, or multifactorial, and for which scientific understanding is insufficient to provide valid molecular targets.

Keywords: BuqiTongluo granule; basket design; efficacy; herbal medicine; randomized controlled trial.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Liu, Zhou, Feng, Zhang, Zhang and Gao.

Figures

FIGURE 1
FIGURE 1
The flowchart of participants disposition throughout the study.

References

    1. Bijur P. E., Silver W., Gallagher E. J. (2001). Reliability of the Visual Analog Scale for Measurement of Acute Pain. Acad. Emerg. Med. 8, 1153–1157. 10.1111/j.1553-2712.2001.tb01132.x
    1. Bril V., Perkins B. A. (2002). Validation of the Toronto Clinical Scoring System for Diabetic Polyneuropathy. Diabetes Care 25 (11), 2048–2052. 10.2337/diacare.25.11.2048
    1. Chan A. W., Tetzlaff J. M., Gøtzsche P. C., Altman D. G., Mann H., Berlin J. A., et al. (2013). SPIRIT 2013 Explanation and Elaboration: Guidance for Protocols of Clinical Trials. BMJ 346 (jan08 15), e7586. 10.1136/bmj.e7586
    1. Cunanan K. M., Iasonos A., Shen R., Begg C. B., Gönen M. (2017). An Efficient Basket Trial Design. Stat. Med. 36 (10), 1568–1579. 10.1002/sim.7227
    1. Dong Y., Tang D., Zhang N., Li Y., Zhang C., Li L., et al. (2013). Phytochemicals and Biological Studies of Plants in Genus Hedysarum. Chem. Cent. J. 7 (1), 124. 10.1186/1752-153x-7-124
    1. Executive summary (2014). Standards of Medical Care in Diabetes--2014. Diabetes Care 37 (Suppl. 1), S5–S13. 10.2337/dc14-S005
    1. Fan L., Zhang F., Sun X. (2014). Study Progress on Stroke with Syndrome of Qi Deficiency and Blood Stasis. World Chin. Med. 9 (02), 257–260. 10.3969/j.issn.1673-7202.2014.02.036
    1. Hao G. M., Liu Y. G., Wu Y., Xing W., Guo S. Z., Wang Y., et al. (2017). The Protective Effect of the Active Components of ERPC on Diabetic Peripheral Neuropathy in Rats. J. Ethnopharmacol 202 (Complete), 162–171. 10.1016/j.jep.2017.03.015
    1. Jiang M., Zhang C., Zheng G., Guo H., Li L., Yang J., et al. (2014). Traditional Chinese Medicine Zheng in the Era of Evidence-Based Medicine: A Literature Analysis. Evidence-Based Complementary Alternative Medicine 2012, 9. 10.1155/2012/409568
    1. Kasner S. E. (2006). Clinical Interpretation and Use of Stroke Scales. Lancet Neurol. 5 (7), 603–612. 10.1016/s1474-4422(06)70495-1
    1. Knuuti J., Wijns W., Saraste A., Capodanno D., Barbato E., Funck-Brentano C., et al. (2020). 2019 ESC Guidelines for the Diagnosis and Management of Chronic Coronary Syndromes. Eur. Heart J. 41 (3), 407–477. 10.1093/eurheartj/ehz425
    1. Li L., Wang J., Ren J., Xiang J., Tang Y., Liu J., et al. (2007). Metabonomics Analysis of the Urine of Rats with Qi Deficiency and Blood Stasis Syndrome Based on NMR Techniques. Chin. Sci. Bull. 52 (22), 3068–3073. 10.1007/s11434-007-0389-4
    1. Miao G. Z., Liang X. Z., Wang Y. H. (2003). Clinical Observation on Treatment of Diabetic Peripheral Neuropathy with Qi-Supplementing and Blood-Activating Therapy. Zhongguo Zhong Xi Yi Jie He Za Zhi 23 (11), 826–828.
    1. Miao J., Cheng L., Chi Z., Jing Y., Yong T., Lu A., et al. (2012). Syndrome Differentiation in Modern Research of Traditional Chinese Medicine. J. Ethnopharmacology 140 (3), 634–642. 10.1016/j.jep.2012.01.033
    1. Park J. J. H., Hsu G., Siden E. G., Thorlund K., Mills E. J. (2020). An Overview of Precision Oncology Basket and Umbrella Trials for Clinicians. CA Cancer J. Clin. 70, 125–137. 10.3322/caac.21600
    1. Sacco R. L., Kasner S. E., Broderick J. P., Caplan L. R., Connors J. J., Culebras A., et al. (2013). An Updated Definition of Stroke for the 21st century: a Statement for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke 44 (7), 2064–2089. 10.1161/STR.0b013e318296aeca
    1. The State Drug Administration (2002). Guideline for Clinical Research of New Chinese Medicine. Beijing: China Medical Science Press.
    1. Uyttenboogaart M., Stewart R. E., Vroomen P. C., De Keyser J., Luijckx G. J. (2005). Optimizing Cutoff Scores for the Barthel Index and the Modified Rankin Scale for Defining Outcome in Acute Stroke Trials. Stroke 36 (9), 1984–1987. 10.1161/01.STR.0000177872.87960.61
    1. Wan J. B., Lee S. M., Wang J. D., Wang N., He C. W., Wang Y. T., et al. (2009). Panax Notoginseng Reduces Atherosclerotic Lesions in ApoE-Deficient Mice and Inhibits TNF-Alpha-Induced Endothelial Adhesion Molecule Expression and Monocyte Adhesion. J. Agric. Food Chem. 57 (15), 6692–6697. 10.1021/jf900529w
    1. Wang Q.-r. (2007). in Yi Lin Gai Cuo (Correcting the Errors in the Forest of Medicine) (Chinese and English Edition. Editors Yuhsin Chung H. O. S. B., Flaws T. B.. 1 ed. (Boulder, Colorado: Blue Poppy Press; ).
    1. Wang S., Liu Q., Guo S., Zhou L., Gao Y. (2015). Item Selection Analysis of Qi Deficiency and Blood Stasis Syndrome Evaluation Scale. Jilin J. Traditional Chin. Med. 35 (07), 656–660. 10.13463/j.cnki.jlzyy.2015.07.003
    1. Wang Z., Zhang P., Kou Y., Yin X., Han N., Jiang B. (2013). Hedysari Extract Improves Regeneration after Peripheral Nerve Injury by Enhancing the Amplification Effect. PLoS One 8 (7), e67921. 10.1371/journal.pone.0067921
    1. Wei S. Y., Zhang P. X., Han N., Dang Y., Zhang H. B., Zhang D. Y., et al. (2009). Effects of Hedysari Polysaccharides on Regeneration and Function Recovery Following Peripheral Nerve Injury in Rats. Am. J. Chin. Med. 37 (1), 57–67. 10.1142/S0192415X09006618
    1. Xie P. M. J. R. X. L. Y. (2020). Wang Yongyan's Experience in Treating Stroke: Case Series of Chinese Medicine Tonify Qi and Promote Blood Circulation. J. Beijing Univ. Traditional Chin. Medicine(Clinical Medicine) 27 (3), 4.
    1. Yuan B. (2021). Towards a Clinical Efficacy Evaluation System Adapted for Personalized Medicine. Pharmgenomics Pers Med. 14, 487–496. 10.2147/pgpm.S304420
    1. Zhai X., Wang X., Wang L., Xiu L., Wang W., Pang X. (2020). Treating Different Diseases With the Same Method-A Traditional Chinese Medicine Concept Analyzed for its Biological Basis. Front. Pharmacol. 11, 946. 10.3389/fphar.2020.00946
    1. Zhang H., Wang W. R., Lin R., Zhang J. Y., Ji Q. L., Lin Q. Q., et al. (2010). Buyang Huanwu Decoction Ameliorates Coronary Heart Disease with Qi Deficiency and Blood Stasis Syndrome by Reducing CRP and CD40 in Rats. J. Ethnopharmacol 130 (1), 98–102. 10.1016/j.jep.2010.04.017
    1. Zhou D., Cen K., Liu W., Liu F., Liu R., Sun Y., et al. (2021). Xuesaitong Exerts Long-Term Neuroprotection for Stroke Recovery by Inhibiting the ROCKII Pathway, In Vitro and In Vivo . J. Ethnopharmacol 272 (3), 113943. 10.1016/j.jep.2021.113943
    1. Zhou W., Wang Y. (2014). A Network-Based Analysis of the Types of Coronary Artery Disease from Traditional Chinese Medicine Perspective: Potential for Therapeutics and Drug Discovery. J. Ethnopharmacol 151 (1), 66–77. 10.1016/j.jep.2013.11.007

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa